From 2017 to 2024, newly diagnosed multiple myeloma (MM) patients rapidly received quadruplet therapies over triplets, with ...

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer ...

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National ...

MM survival rates have improved with the introduction of novel agents. Treatment of MM within the first year is associated with improved survival. New research has concluded that, despite more ...

Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following a single infusion as early as second lineData suggest ...

Median progression-free survival was 22 months, overall survival was 152 months among patients with newly diagnosed MM.

Common manifestations and complications of multiple myeloma (MM) can include bone complications, hypercalcemia, renal insufficiency, infection, skeletal lesions and anemia. Other less common ...

(GLOBE NEWSWIRE) -- "Relapsed/Refractory Multiple Myeloma (RRMM) is difficult to manage because there's no clear, consistent guidance -- ask five academic physicians and you'll get five different ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Relapsed/refractory multiple myeloma (RRMM) doesn’t have a cure. But many treatments can ease symptoms and slow the cancer’s growth. If the medicines you’re taking stop working, you and your doctor ...

In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment ...